Increased Endothelin: Nitric Oxide Ratio Is Associated with Erythropoietin-Induced Hypertension in Hemodialysis Patients

References

• Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 1989; 321: 158–163
   Google Scholar
• Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987; 316: 73–78
   Google Scholar
• Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 1986; 22: 1175–1177
   Google Scholar
• Sundal E., Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a european multicenter study of 150 hemodialysis-dependent patients. Nephrol. Dial. Transplant. 1989; 4: 979–987
   Google Scholar
• Raine A.E., Roger S.D. Effects of erythropoietin on blood pressure. Am. J. Kidney Dis. 1991; 18(4 suppl. 1)76–83
   Google Scholar
• Abraham P.A., Macres M.G. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J. Am. Soc. Nephrol. 1991; 2: 927–936
   Google Scholar
• London G.M., Zins B., Pannier B., Naret C., Berthelot J.M., Jacqot C., Safar M., Drueke T.B. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int. 1989; 36: 878–882
   Google Scholar
• Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415
   Google Scholar
• Warrens A.N., Cassidy M.J., Takahashi K., Ghatei M.A., Bloom S.R. Endothelin in renal failure. Nephrol. Dial. Transplant. 1990; 5: 418–422
   Google Scholar
• Saito Y., Kazuwa N., Shirakami G., Mukoyama M., Arai H., Hosoda K., Suga S., Ogawa Y., Imura H. Endothelin in patients with chronic renal failure. J. Cardiovasc. Pharmacol. 1991; 17(suppl. 7)S437–S439
   Google Scholar
• Deray G., Carayon A., Maistre G., Benhmida M., Masson F., Barthelemy C., Petitclerc G., Jacobs C. Endothelin in chronic renal failure. Nephrol. Dial. Transplant. 1992; 7: 300–305
   Google Scholar
• Mortensen L.H., Pawloski C.M., Kanagy N.L., Fink G.D. Chronic hypertension produced by infusion of endothelin in rats. Hypertension 1990; 15: 729–733
   Google Scholar
• Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erytheopoietin has a mitigenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 1990; 87: 5978–5982
   Google Scholar
• Vaziri N.D., Zhou X.J., Smith J., Oveisi F., Baldwin K., Purdy R.E. In vivo and in vitro pressor effects of erythropoietin in rats. Am. J. Physiol. 1995; 269: F838–F845
   Google Scholar
• Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and (15N) nitrate in biological fluids. Anal. Biochem. 1982; 126: 131–138
   Google Scholar
• Eggena P., Willsey P., Jamgotchian N., Truckenbrod L., Hu M.S., Barrett J.D., Eggena M.P., Clegg K., Nakhoul F., Lee D.B.N. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am. J. Physiol. 1991; 261: E642–E646
   Google Scholar
• Heidenreich S., Rahn K.H., Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 1991; 39: 259–265
   Google Scholar
• Carlini R.G., Obialo C.I., Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens. 1993; 6: 103–107
   Google Scholar
• Carlini R.G., Dusso A.S., Obialo C.I., Alvarez U.M., Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993; 43: 1010–1014
   Google Scholar
• Takahashi K., Totsune K., Imai Y., Sone M., Nozuki M., Murakami O., Sekino H., Mouri T. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin. Sci. 1993; 84: 47–50
   Google Scholar
• Bode-Boger S.M., Boger R.H., Kuhn M., Radermacher J., Frolich J.C. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996; 50: 1255–1261
   Google Scholar
• Lopez Ongil S.L., Saura M., Lamas S., Rodriguez Puyol M., Rodorigez Puyol D. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells. Exp. Nephrol. 1996; 4: 37–42
   Google Scholar
• Zhou X.J., Pandian D., Wang X.Q., Vaziri N.D. Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or arial natriuretic peptide levels. J. Am. Soc. Nephrol. 1997; 8: 901–905
   Google Scholar
• Brunet P., Lorec A.M., Leonetti F., Roubicek C., Jaber K., Roux F., Berland Y. Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin. Nephrol. Dial. Transplant. 1994; 9: 650–654
   Google Scholar
• Hand M.F., Haynes W.G., Johnstone H.A., Anderton J.L., Webb D.J. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int. 1995; 48: 806–813
   Google Scholar
• Lai K.N., Lui S.F., Leung J.C., Law E., Nicholls M.G. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 57: 394–400
   Google Scholar
• Wang X.Q., Vaziri N.D. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894–899
   Google Scholar
• Del Castillo D., Raij L., Shultz P.J., Tolin J.P. The pressor effect of recombinant human erythropoietin is not due to deceased activity of the endogenous nitric oxide system. Nephrol. Dial. Transplant. 1995; 10: 505–508
   Google Scholar
• Tsukahara H., Hiraoka M., Hori C., Hata I., Okada T., Gejyo F., Sudo M. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand. J. Clin. Lab. Invest. 1997; 57: 487–493
   Google Scholar
• Moreau C., Lariviere R., Kingma I., Grose J.H., Lebel M. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats. Clin. Exp. Hypertens. 2000; 22: 663–674
   Google Scholar
• Kim S.W., Lee J., Kang D.G., Jung K., Kim N.H., Suh S.P., Choi K.C., Kang Y.J. Erythropoietin does not affect nitric oxide system in rats with chronic renal failure. J. Korean Med. Sci. 2000; 15: 183–188
   Google Scholar
• Rossi G.P., Seccia T.M., Nussdorfer G.G. Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int. Rev. Cytol. 2001; 209: 241–272
   Google Scholar